Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Mirvetuximab soravtansine shows promise in FRα-positive, platinum-sensitive...

Dr Angeles Alvarez Secord - Duke Cancer Center, Durham, USA

Mirvetuximab soravtansine shows promise in FRα-positive, platinum-sensitive ovarian cancer ( Dr Angeles Alvarez Secord - Duke Cancer Center, Durham, USA )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof...

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

TNBC: Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab...

Prof Peter Schmid - Barts Cancer Institute, London, UK

TNBC: Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OS compared to neoadjuvant chemo alone ( Prof Peter Schmid - Barts Cancer Institute, London, UK )

ESMO 2024: Latest updates in mRCC

Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane...

ESMO 2024: Latest updates in mRCC ( Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane Oudard )

TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate...

Prof Josep Llovet - Hospital Clinic Barcelona, Barcelona, Spain

TACE combined with lenvatinib-pembrolizumab shows improved PFS in intermediate stage liver cancer ( Prof Josep Llovet - Hospital Clinic Barcelona, Barcelona, Spain )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates...

Prof Nicolas Girard - Institut Curie, Paris, France

Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates improved clinical benefit in NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Patient reported outcomes for telisotuzumab vedotin in c-Met protein...

Prof Nicolas Girard - Institut Curie, Paris, France

Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Nivolumab plus ipilimumab improves efficacy versus standard of care in non...

Prof Lothar Bergmann - University Hospital Frankurt, Frankfurt am Main, Germany

Nivolumab plus ipilimumab improves efficacy versus standard of care in non-clear-cell renal cell carcinomas ( Prof Lothar Bergmann - University Hospital Frankurt, Frankfurt am Main, Germany )

Repeat immune checkpoint inhibitor therapy not recommended for aRCC

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Repeat immune checkpoint inhibitor therapy not recommended for aRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Bladder cancer updates from the first half of 2024

Prof Alison Birtle, Dr Ignacio Durán, Dr Patrizia Giannatempo

Bladder cancer updates from the first half of 2024 ( Prof Alison Birtle, Dr Ignacio Durán, Dr Patrizia Giannatempo )

More from ecancer